LHCGR
ENSG00000138039
Target class
GPCR
Chromosome
2
Approved drugs
5
Clinical candidates (approved and in development)
5
- Approved drugs
- 5
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- Yes
- Target name
- LHCGR
- Gene name
- Luteinizing hormone/choriogonadotropin receptor
- Gene symbol
- LHCGR
- Previous gene symbols
- HHG
- Protein name
- Lutropin-choriogonadotropic hormone receptor (LH/CG-R) (Luteinizing hormone receptor) (LHR) (LSH-R)
- LHR
- LCGR
- LGR2
- ULG5
- Gene biotype
- Protein coding
- Gene family
- Glycoprotein hormone receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 4
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 5.24
- Tissue specificity (Gini)
- 0.813
- Tissue specificity (tau)
- 0.949
- KEGG gene identifiers
- hsa:3973
- Protein interaction confidence
- 0.827415
- Protein interaction partners
- 41
- R-HSA-375281
- R-HSA-418555
- End position
- 48755730
- Start position
- 48686774
- Chromosome
- 2
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein .
- Plasma membrane
Publication evidence
- PubMed 11847099
- Tissue specificity (tau)
- 0.949121
- Expression inequality (Gini)
- 0.813199
Expression in transcripts per million
- Nerve - Tibial
- 5.24
- Esophagus - Muscularis
- 4.56
- Ovary
- 1.92
- Esophagus - Gastroesophageal Junction
- 1.7
- Testis
- 0.87
Expression in transcripts per million
- Nerve - Tibial5.24
- Esophagus - Muscularis4.56
- Ovary1.92
- Esophagus - Gastroesophageal Junction1.7
- Testis0.87
- Adipose - Subcutaneous0.74
- Adipose - Visceral (Omentum)0.66
- Bladder0.38
- Breast - Mammary Tissue0.35
- Thyroid0.31
- Pituitary0.28
- Adrenal Gland0.22
- Skin - Sun Exposed (Lower leg)0.19
- Colon - Sigmoid0.18
- Esophagus - Mucosa0.15
- Skin - Not Sun Exposed (Suprapubic)0.1
- Artery - Aorta0.09
- Artery - Coronary0.09
- Brain - Hypothalamus0.08
- Lung0.08
- Prostate0.08
- Cervix - Endocervix0.08
- Uterus0.07
- Brain - Substantia nigra0.07
- Brain - Caudate (basal ganglia)0.07
And 29 more, listed on the interactive page.
- GO:0007186
- GO:0007187
- GO:0008584
- GO:0030539
- GO:0042700
- GO:0050890
- GO:0071373
- GO:0005768
- GO:0005886
Molecular functions
- GO:0004964
Related records
Trials (263)
- A Clinical Trial to Determine the Effect of Lutropin Alfa on Embryo Quality and Implantation Rate in Advanced Reproductive Age
- A Phase 2 Trial to Evaluate if Corifollitropin Alfa (Org 36286), Followed by a Low Daily Dose of hCG or Recombinant FSH Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility (P05693)
- A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age
- A Proof of Concept Study of Serum Progesterone Levels for IVF/ICSI Following HCG Trigger for Oocyte Maturation
- A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies
- A Randomised, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of Combined Treatment of Lutropin Alpha and Recombinant Human Luteinizing Hormone in the Middle of the Controlled Ovarian Stimulation Follicular Phase in Women With Reduced Ovarian Reserve
- A Randomized Controlled Study of Different Trigger Modes of Antagonist Regimen in Patients With Low Ovarian Reserve
- A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial
- A Study Comparing MENOPUR in a Pen Formulation With a Powder and Solvent Formulation in Healthy Women
- A Study of Human Chorionic Gonadotrophin as Luteal Phase Support in Frozen Embryo Transfer
- A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)
- A Study of the Efficacy and Safety of Highly Purified Menotrophin Versus Recombinant Follitropin Alfa
- A Study on Efficacy and Safety of Menopur® Multidose in Korean Female Patients With Infertility
- A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)
- A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation
- A Study to Evaluate Safety and Efficacy of Recombinant Human Luteinizing Hormone (r-hLH) Compared With Urinary Human Chorionic Gonadotrophin (u-hCG) to Trigger Ovulation in Infertile Women
- A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)
- A Study to Measure Relationship Between Antimüllerian Hormone and Initial Dose of Menopur®
- A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism
- A Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 Versus Day 6 in Women Undergoing Assisted Reproductive Technique
Drugs (5)
- Choriogonadotropin alfa Luteinizing hormone/Choriogonadotropin receptor agonist
- Gonadotropin, chorionic Luteinizing hormone/Choriogonadotropin receptor agonist
- LH (menotropins) Luteinizing hormone/Choriogonadotropin receptor agonist
- Lutropin alfa Luteinizing hormone/Choriogonadotropin receptor agonist
- Menotropins Luteinizing hormone/Choriogonadotropin receptor agonist